Neurometrix, Inc. (NURO): Shai Gozani , CEO of Neurometrix, Inc. purchased 12,000 shares on May 18, 2016. The Insider buying transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.55 per share for a total value of $18,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 28, 2015, Thomas T Higgins (CFO) purchased 4,500 shares at $0.92 per share price.On Aug 11, 2015, Shai Gozani (CEO) purchased 16,300 shares at $0.91 per share price.
Neurometrix Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Neurometrix Inc which led to swings in the share price. The shares opened for trading at $1.6199 and hit $1.6199 on the upside , eventually ending the session at $1.56, with a gain of 2.63% or 0.04 points. The heightened volatility saw the trading volume jump to 13,477 shares. The 52-week high of the share price is $5.1596 and the company has a market cap of $6,848 M . The 52-week low of the share price is at $1.35.
NeuroMetrix Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain nerve diseases and sleep disorders. The Company is engaged in product development manufacturing regulatory affairs and compliance sales and marketing and customer support. The Company sells medical devices and after-market consumable products and accessories. The Company has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. The Company’s products include Quell SENSUS DPNCheck and ADVANCE System.